Status:
COMPLETED
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections un...
Eligibility Criteria
Inclusion
- Healthy men and women 18 to 60 yrs with mild allergic asthma
- only asthma med is short-acting bronchodilator used not more than twice weekly
- FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction
Exclusion
- Upper respiratory infection or asthma exacerbation with 4 weeks of screening
- Serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of test article administration
- Positive radiographic findings indicative of respiratory disease other than asthma
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00725582
Start Date
September 1 2008
End Date
June 1 2009
Last Update
June 2 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.